Accelerating life sciences research | OpenAI

At OpenAI, we believe that AI can meaningfully accelerate life science innovation. To test this belief, we collaborated with the Applied AI team at Retro Bio⁠ (opens in a new window) , a longevity biotech startup, to create and research the impact of GPT‑4b micro, a miniature version of GPT‑4o specialized for protein engineering. We are excited to share that we’ve successfully leveraged GPT‑4b micro to design novel and significantly enhanced variants of the Yamanaka factors, a set of proteins which led to a Nobel Prize for their role in generating induced pluripotent stem cells (iPSCs) and rejuvenating cells. They have also been used to develop therapeutics to combat blindness⁠ (opens in a new window) , reverse diabetes⁠ (opens in a new window) , treat infertility⁠ (opens in a new window) , and address organ shortages⁠ (opens in a new window) . In vitro, these redesigned proteins achieved greater than a 50-fold higher expression of stem cell reprogramming markers than wild-type control

At OpenAI, we believe that AI can meaningfully accelerate life science innovation. To test this belief, we collaborated with the Applied AI team at Retro Bio⁠ (opens in a new window) , a longevity biotech startup, to create and research the impact of GPT‑4b micro, a miniature version of GPT‑4o specialized for protein engineering. We are excited to share that we’ve successfully leveraged GPT‑4b micro to design novel and significantly enhanced variants of the Yamanaka factors, a set of proteins which led to a Nobel Prize for their role in generating induced pluripotent stem cells (iPSCs) and rej